The clinical management of invasive mold infection in children with cancer or undergoing hematopoietic stem cell transplantation

References

• Girmenia C, Bertaina A, Piciocchi A, et al. Incidence, risk factors and outcome of pre-engraftment gram-negative bacteremia after allogeneic and autologous hematopoietic stem cell transplantation: an Italian prospective multicenter survey. Clin Infect Dis. 2017;65:1884–1896.
   PubMed Web of Science ®Google Scholar
• Koehler P, Hamprecht A, Bader O, et al. Epidemiology of invasive aspergillosis and azole resistance in patients with acute leukaemia: the SEPIA Study. Int J Antimicrob Agents. 2017;49:218–223.
   PubMed Web of Science ®Google Scholar
• Melendez-Munoz R, Marchalik R, Jerussi T, et al. Cytomegalovirus infection incidence and risk factors across diverse hematopoietic cell transplantation platforms using a standardized monitoring and treatment approach: a comprehensive evaluation from a single institution. Biol Blood Marrow Transplant. 2019;25(3):577-586. doi: 10.1016/j.bbmt.2018.10.011..
   PubMedGoogle Scholar
• Castagnola E, Bagnasco F, Faraci M, et al. Incidence of bacteremias and invasive mycoses in children undergoing allogeneic hematopoietic stem cell transplantation: a single center experience. Bone Marrow Transplant. 2008;41:339–347.
   PubMed Web of Science ®Google Scholar
• Castagnola E, Cappelli B, Erba D, et al. Cytomegalovirus infection after bone marrow transplantation in children. Hum Immunol. 2004;65:416–422.
   PubMed Web of Science ®Google Scholar
• Groll AH, Castagnola E, Cesaro S, et al. Fourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or allogeneic haemopoietic stem-cell transplantation. Lancet Oncol. 2014;15:e327–e340.
   PubMed Web of Science ®Google Scholar
• Lehrnbecher T, Phillips R, Alexander S, et al. Guideline for the management of fever and neutropenia in children with cancer and/or undergoing hematopoietic stem-cell transplantation. J Clin Oncol. 2012;30:4427–4438.
   PubMed Web of Science ®Google Scholar
• Science M, Robinson PD, MacDonald T, et al. Guideline for primary antifungal prophylaxis for pediatric patients with cancer or hematopoietic stem cell transplant recipients. Pediatr Blood Cancer. 2014;61:393–400.
   PubMed Web of Science ®Google Scholar
• Lehrnbecher T, Robinson P, Fisher B, et al. Guideline for the management of fever and neutropenia in children with cancer and hematopoietic stem-cell transplantation recipients: 2017 update. J Clin Oncol. 2017;35:2082–2094.
   PubMed Web of Science ®Google Scholar
• Lehrnbecher T, Frank C, Engels K, et al. Trends in the postmortem epidemiology of invasive fungal infections at a university hospital. J Infect. 2010;61:259–265.
   PubMed Web of Science ®Google Scholar
• Groll AH, Shah PM, Mentzel C, et al. Trends in the postmortem epidemiology of invasive fungal infections at a university hospital. J Infect. 1996;33:23–32.
   PubMed Web of Science ®Google Scholar
• Zaoutis TE, Heydon K, Chu JH, et al. Epidemiology, outcomes, and costs of invasive aspergillosis in immunocompromised children in the United States, 2000. Pediatrics. 2006;117:e711–e716.
   PubMed Web of Science ®Google Scholar
• Hol JA, Wolfs TF, Bierings MB, et al. Predictors of invasive fungal infection in pediatric allogeneic hematopoietic SCT recipients. Bone Marrow Transplant. 2014;49:95–101.
   PubMed Web of Science ®Google Scholar
• Fisher BT, Robinson PD, Lehrnbecher T, et al. Risk factors for invasive fungal disease in pediatric cancer and hematopoietic stem cell transplantation: a systematic review. J Pediatric Infect Dis Soc. 2018;7:191–198.
   PubMed Web of Science ®Google Scholar
• Hale KA, Shaw PJ, Dalla-Pozza L, et al. Epidemiology of paediatric invasive fungal infections and a case-control study of risk factors in acute leukaemia or post stem cell transplant. Br J Haematol. 2010;149:263–272.
   PubMed Web of Science ®Google Scholar
• Grigull L, Beier R, Schrauder A, et al. Invasive fungal infections are responsible for one-fifth of the infectious deaths in children with ALL. Mycoses. 2003;46:441–446.
   PubMed Web of Science ®Google Scholar
• Lehrnbecher T, Schoning S, Poyer F, et al. Incidence and outcome of invasive fungal diseases in children with hematological malignancies and/or allogeneic hematopoietic stem cell transplantation: results of a prospective multicenter study. Front Microbiol. 2019;10:681.
   PubMed Web of Science ®Google Scholar
• Lehrnbecher T, Becker K, Groll AH. Current algorithms in fungal diagnosis in the immunocompromised host. Methods Mol Biol. 2017;1508:67–84.
   PubMedGoogle Scholar
• De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European organization for research and treatment of cancer/invasive fungal infections cooperative group and the national institute of allergy and infectious diseases mycoses study group (EORTC/MSG) consensus group. Clin Infect Dis. 2008;46:1813–1821.
   PubMed Web of Science ®Google Scholar
• Marchetti O, Lamoth F, Mikulska M, et al. ECIL recommendations for the use of biological markers for the diagnosis of invasive fungal diseases in leukemic patients and hematopoietic SCT recipients. Bone Marrow Transplant. 2012;47:846–854.
   PubMed Web of Science ®Google Scholar
• Viscoli C, Machetti M, Cappellano P, et al. False-positive galactomannan platelia Aspergillus test results for patients receiving piperacillin-tazobactam. Clin Infect Dis. 2004;38:913–916.
   PubMed Web of Science ®Google Scholar
• Duarte RF, Sanchez-Ortega I, Cuesta I, et al. Serum galactomannan-based early detection of invasive aspergillosis in hematology patients receiving effective antimold prophylaxis. Clin Infect Dis. 2014;59:1696–1702.
   PubMed Web of Science ®Google Scholar
• Lehrnbecher T, Robinson PD, Fisher BT, et al. Galactomannan, beta-D-glucan, and polymerase chain reaction-based assays for the diagnosis of invasive fungal disease in pediatric cancer and hematopoietic stem cell transplantation: a systematic review and meta-analysis. Clin Infect Dis. 2016;63:1340–1348.
   PubMed Web of Science ®Google Scholar
• Leeflang MM, Debets-Ossenkopp YJ, Wang J, et al. Galactomannan detection for invasive aspergillosis in immunocompromised patients. Cochrane Database Syst Rev. 2015;12:CD007394.
   PubMed Web of Science ®Google Scholar
• de Mol M, de Jongste JC, van Westreenen M, et al. Diagnosis of invasive pulmonary aspergillosis in children with bronchoalveolar lavage galactomannan. Pediatr Pulmonol. 2013;48:789–796.
   PubMed Web of Science ®Google Scholar
• Reinwald M, Spiess B, Heinz WJ, et al. Aspergillus PCR-based investigation of fresh tissue and effusion samples in patients with suspected invasive aspergillosis enhances diagnostic capabilities. J Clin Microbiol. 2013;51:4178–4185.
   PubMed Web of Science ®Google Scholar
• Viscoli C, Machetti M, Gazzola P, et al. Aspergillus galactomannan antigen in the cerebrospinal fluid of bone marrow transplant recipients with probable cerebral aspergillosis. J Clin Microbiol. 2002;40:1496–1499.
   PubMed Web of Science ®Google Scholar
• Roilides E, Pavlidou E, Papadopoulos F, et al. Cerebral aspergillosis in an infant with corticosteroid-resistant nephrotic syndrome. Pediatr Nephrol. 2003;18:450–453.
   PubMed Web of Science ®Google Scholar
• Huppler AR, Fisher BT, Lehrnbecher T, et al. Role of molecular biomarkers in the diagnosis of invasive fungal diseases in children. J Pediatric Infect Dis Soc. 2017;6:S32–S44.
   PubMed Web of Science ®Google Scholar
• Smith PB, Benjamin DK Jr., Alexander BD, et al. Quantification of 1,3-beta-D-glucan levels in children: preliminary data for diagnostic use of the beta-glucan assay in a pediatric setting. Clin Vaccine Immunol. 2007;14:924–925.
   PubMed Web of Science ®Google Scholar
• Koltze A, Rath P, Schoning S, et al. Beta-D-glucan screening for the detection of invasive fungal disease in children undergoing allogeneic hematopoietic stem cell transplantation. J Clin Microbiol. 2015.
   PubMed Web of Science ®Google Scholar
• Calitri C, Caviglia I, Cangemi G, et al. Performance of 1,3-beta-D-glucan for diagnosing invasive fungal diseases in children. Mycoses. 2017;60:789–795.
   PubMed Web of Science ®Google Scholar
• Buchheidt D, Reinwald M, Spiess B, et al. Biomarker-based diagnostic work-up of invasive pulmonary aspergillosis in immunocompromised paediatric patients–is Aspergillus PCR appropriate? Mycoses. 2016;59:67–74.
   PubMed Web of Science ®Google Scholar
• Caillot D, Casasnovas O, Bernard A, et al. Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery. J Clin Oncol. 1997;15:139–147.
   PubMed Web of Science ®Google Scholar
• Heussel CP, Kauczor HU, Heussel GE, et al. Pneumonia in febrile neutropenic patients and in bone marrow and blood stem-cell transplant recipients: use of high-resolution computed tomography. J Clin Oncol. 1999;17:796–805.
   PubMed Web of Science ®Google Scholar
• Burgos A, Zaoutis TE, Dvorak CC, et al. Pediatric invasive aspergillosis: a multicenter retrospective analysis of 139 contemporary cases. Pediatrics. 2008;121:e1286–1294.
   PubMed Web of Science ®Google Scholar
• Pearce MS, Salotti JA, Little MP, et al. Radiation exposure from CT scans in childhood and subsequent risk of leukaemia and brain tumours: a retrospective cohort study. Lancet. 2012;380:499–505.
   PubMed Web of Science ®Google Scholar
• Broenen E, Mavinkurve-Groothuis A, Kamphuis-van Ulzen K, et al. Screening of the central nervous system in children with invasive pulmonary aspergillosis. Med Mycol Case Rep. 2014;4:8–11.
   PubMedGoogle Scholar
• Lauten M, Attarbaschi A, Cario G, et al. Invasive mold disease of the central nervous system in children and adolescents with cancer or undergoing hematopoietic stem cell transplantation: analysis of 29 contemporary patients. Pediatr Blood Cancer. 2019;e27806.
   PubMedGoogle Scholar
• Reinwald M, Hummel M, Kovalevskaya E, et al. Therapy with antifungals decreases the diagnostic performance of PCR for diagnosing invasive aspergillosis in bronchoalveolar lavage samples of patients with haematological malignancies. J Antimicrob Chemother. 2012;67:2260–2267.
   PubMed Web of Science ®Google Scholar
• Chellapandian D, Lehrnbecher T, Phillips B, et al. Bronchoalveolar lavage and lung biopsy in patients with cancer and hematopoietic stem-cell transplantation recipients: a systematic review and meta-analysis. J Clin Oncol. 2015;33:501–509.
   PubMed Web of Science ®Google Scholar
• Ullmann AJ, Aguado JM, Arikan-Akdagli S, et al. Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline. Clin Microbiol Infect. 2018;24(Suppl 1):e1–e38.
   PubMed Web of Science ®Google Scholar
• Rausch CR, Kontoyiannis DP. Prolonged voriconazole treatment in a patient with chronic lymphocytic leukemia resulting in a litany of chronic overlapping toxicities. J Oncol Pharm Pract. 2019;25(3):747-753. doi: 10.1177/1078155218762624.
   PubMed Web of Science ®Google Scholar
• Chowdhary A, Sharma C, Meis JF. Azole-resistant aspergillosis: epidemiology, molecular mechanisms, and treatment. J Infect Dis. 2017;216:S436–S444.
   PubMed Web of Science ®Google Scholar
• Goyal RK, Gehris RP, Howrie D, et al. Phototoxic dermatoses in pediatric BMT patients receiving voriconazole. Pediatr Blood Cancer. 2014;61:1325–1328.
   PubMed Web of Science ®Google Scholar
• Bochennek K, Balan A, Muller-Scholden L, et al. Micafungin twice weekly as antifungal prophylaxis in paediatric patients at high risk for invasive fungal disease. J Antimicrob Chemother. 2015;70:1527–1530.
   PubMed Web of Science ®Google Scholar
• Bochennek K, Tramsen L, Schedler N, et al. Liposomal amphotericin B twice weekly as antifungal prophylaxis in pediatric high risk patients. Clin Microb Infect. 2011;17:1868–1874.
   Google Scholar
• Lehrnbecher T, Bochennek K, Klingebiel T, et al. Extended dosing regimens for fungal prophylaxis. Clin Microbiol Rev. 2019;32(3). pii: e00010-19. doi: 10.1128/CMR.00010-19.
   PubMedGoogle Scholar
• Allinson K, Kolve H, Gumbinger HG, et al. Secondary antifungal prophylaxis in paediatric allogeneic haematopoietic stem cell recipients. J Antimicrob Chemother. 2008;61:734–742.
   PubMed Web of Science ®Google Scholar
• Maertens J, Marchetti O, Herbrecht R, et al. European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3–2009 update. Bone Marrow Transplant. 2011;46:709–718.
   PubMed Web of Science ®Google Scholar
• Lehrnbecher T, Groll AH. Invasive fungal diseases in immunocompromised children: should we continue with empirical treatment or rely more on diagnostics? Lancet Child Adolesc Health. Forthcoming.
   Google Scholar
• Caselli D, Cesaro S, Ziino O, et al. A prospective, randomized study of empirical antifungal therapy for the treatment of chemotherapy-induced febrile neutropenia in children. Br J Haematol. 2012;158:249–255.
   PubMed Web of Science ®Google Scholar
• Maertens JA, Madero L, Reilly AF, et al. A randomized, double-blind, multicenter study of caspofungin versus liposomal amphotericin B for empiric antifungal therapy in pediatric patients with persistent fever and neutropenia. Pediatr Infect Dis J. 2010;29:415–420.
   PubMed Web of Science ®Google Scholar
• Sandler ES, Mustafa MM, Tkaczewski I, et al. Use of amphotericin B colloidal dispersion in children. J Pediatr Hematol Oncol. 2000;22:242–246.
   PubMed Web of Science ®Google Scholar
• Prentice HG, Hann IM, Herbrecht R, et al. A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients. Br J Haematol. 1997;98:711–718.
   PubMed Web of Science ®Google Scholar
• White MH, Bowden RA, Sandler ES, et al. Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia. Clin Infect Dis. 1998;27:296–302.
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Finberg RW, Arndt C, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National institute of allergy and infectious diseases mycoses study group. N Engl J Med. 1999;340:764–771.
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Teppler H, Donowitz GR, et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med. 2004;351:1391–1402.
   PubMed Web of Science ®Google Scholar
• Cordonnier C, Pautas C, Maury S, et al. Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial. Clin Infect Dis. 2009;48:1042–1051.
   PubMed Web of Science ®Google Scholar
• Santolaya ME, Alvarez AM, Acuna M, et al. Efficacy of pre-emptive versus empirical antifungal therapy in children with cancer and high-risk febrile neutropenia: a randomized clinical trial. J Antimicrob Chemother. 2018;73:2860–2866.
   PubMed Web of Science ®Google Scholar
• Warris A, Lehrnbecher T, Roilides E, et al. ESCMID-ECMM guideline: diagnosis and management of invasive aspergillosis in neonates and children. Clin Microb Infect. 2019. pii: S1198-743X(19)30282-4. doi: 10.1016/j.cmi.2019.05.019.
   Google Scholar
• Barg AA, Malkiel S, Bartuv M, et al. Successful treatment of invasive mucormycosis with isavuconazole in pediatric patients. Pediatr Blood Cancer. 2018;65:e27281.
   PubMed Web of Science ®Google Scholar
• Cornu M, Bruno B, Loridant S, et al. Successful outcome of disseminated mucormycosis in a 3-year-old child suffering from acute leukaemia: the role of isavuconazole? A case report. BMC Pharmacol Toxicol. 2018;19:81.
   PubMed Web of Science ®Google Scholar
• Bodey GP, Buckley M, Sathe YS, et al. Quantitative relationships between circulating leukocytes and infections in patients with acute leukemia. Ann Intern Med. 1966;64:328–340.
   PubMed Web of Science ®Google Scholar
• Pagano L, Caira M, Candoni A, et al. Invasive aspergillosis in patients with acute myeloid leukemia: a SEIFEM-2008 registry study. Haematologica. 2010;95:644–650.
   PubMed Web of Science ®Google Scholar
• Mousset S, Hermann S, Klein SA, et al. Prophylactic and interventional granulocyte transfusions in patients with haematological malignancies and life-threatening infections during neutropenia. Ann Hematol. 2005;84:734–741.
   PubMed Web of Science ®Google Scholar
• Seidel MG, Peters C, Wacker A, et al. Randomized phase III study of granulocyte transfusions in neutropenic patients. Bone Marrow Transplant. 2008;42:679–684.
   PubMed Web of Science ®Google Scholar
• Romani L. Immunity to fungal infections. Nat Rev Immunol. 2011;11:275–288.
   PubMed Web of Science ®Google Scholar
• Girmenia C, Barosi G, Piciocchi A, et al. Primary prophylaxis of invasive fungal diseases in allogeneic stem cell transplantation: revised recommendations from a consensus process by Gruppo Italiano Trapianto Midollo Osseo (GITMO). Biol Blood Marrow Transplant. 2014;20:1080–1088.
   PubMed Web of Science ®Google Scholar
• Hebart H, Bollinger C, Fisch P, et al. Analysis of T-cell responses to Aspergillus fumigatus antigens in healthy individuals and patients with hematologic malignancies. Blood. 2002;100:4521–4528.
   PubMed Web of Science ®Google Scholar
• Perruccio K, Tosti A, Burchielli E, et al. Transferring functional immune responses to pathogens after haploidentical hematopoietic transplantation. Blood. 2005;106:4397–4406.
   PubMed Web of Science ®Google Scholar
• Deo SS, Virassamy B, Halliday C, et al. Stimulation with lysates of Aspergillus terreus, candida krusei and rhizopus oryzae maximizes cross-reactivity of anti-fungal T cells. Cytotherapy. 2016;18:65–79.
   PubMed Web of Science ®Google Scholar
• Gaundar SS, Clancy L, Blyth E, et al. Robust polyfunctional T-helper 1 responses to multiple fungal antigens from a cell population generated using an environmental strain of Aspergillus fumigatus. Cytotherapy. 2012;14:1119–1130.
   PubMed Web of Science ®Google Scholar
• Tramsen L, Koehl U, Tonn T, et al. Clinical-scale generation of human anti-Aspergillus T cells for adoptive immunotherapy. Bone Marrow Transplant. 2009;43:13–19.
   PubMed Web of Science ®Google Scholar
• Ruggeri L, Parisi S, Urbani E, et al. Alloreactive natural killer cells for the treatment of acute myeloid leukemia: from stem cell transplantation to adoptive immunotherapy. Front Immunol. 2015;6:479.
   PubMed Web of Science ®Google Scholar
• Leivas A, Perez-Martinez A, Blanchard MJ, et al. Novel treatment strategy with autologous activated and expanded natural killer cells plus anti-myeloma drugs for multiple myeloma. Oncoimmunology. 2016;5:e1250051.
   PubMed Web of Science ®Google Scholar
• Morrison BE, Park SJ, Mooney JM, et al. Chemokine-mediated recruitment of NK cells is a critical host defense mechanism in invasive aspergillosis. J Clin Invest. 2003;112:1862–1870.
   PubMed Web of Science ®Google Scholar
• Ma LL, Wang CL, Neely GG, et al. NK cells use perforin rather than granulysin for anticryptococcal activity. J Immunol. 2004;173:3357–3365.
   PubMed Web of Science ®Google Scholar
• Schmidt S, Tramsen L, Perkhofer S, et al. Rhizopus oryzae hyphae are damaged by human natural killer (NK) cells, but suppress NK cell mediated immunity. Immunobiology. 2013;218(7):939-44. doi: 10.1016/j.imbio.2012.10.013.
   Web of Science ®Google Scholar
• Schmidt S, Tramsen L, Hanisch M, et al. Human natural killer cells exhibit direct activity against Aspergillus fumigatus hyphae, but not against resting conidia. J Infect Dis. 2011;203:430–435.
   PubMed Web of Science ®Google Scholar
• Bouzani M, Ok M, McCormick A, et al. Human NK cells display important antifungal activity against Aspergillus fumigatus, which is directly mediated by IFN-gamma release. J Immunol. 2011;187:1369–1376.
   PubMed Web of Science ®Google Scholar
• Sung L, Phillips R, Lehrnbecher T. Time for paediatric febrile neutropenia guidelines - children are not little adults. Eur J Cancer. 2011;47:811–813.
   PubMed Web of Science ®Google Scholar
• Heldt S, Hoenigl M. Lateral flow assays for the diagnosis of invasive aspergillosis: current status. Curr Fungal Infect Rep. 2017;11:45–51.
   PubMed Web of Science ®Google Scholar
• Hoenigl M, Eigl S, Heldt S, et al. Clinical evaluation of the newly formatted lateral-flow device for invasive pulmonary aspergillosis. Mycoses. 2018 Jan;61(1):40-43. doi: 10.1111/myc.12704.
   Web of Science ®Google Scholar
• Bacher P, Steinbach A, Kniemeyer O, et al. Fungus-specific CD4(+) T cells for rapid identification of invasive pulmonary mold infection. Am J Respir Crit Care Med. 2015;191:348–352.
   PubMed Web of Science ®Google Scholar
• Potenza L, Barozzi P, Vallerini D, et al. Diagnosis of invasive aspergillosis by tracking Aspergillus-specific T cells in hematologic patients with pulmonary infiltrates. Leukemia. 2007;21:578–581.
   PubMed Web of Science ®Google Scholar
• Rolle AM, Hasenberg M, Thornton CR, et al. ImmunoPET/MR imaging allows specific detection of Aspergillus fumigatus lung infection in vivo. Proc Natl Acad Sci U S A. 2016;113:E1026–1033.
   PubMed Web of Science ®Google Scholar
• Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med. 2007;356:348–359.
   PubMed Web of Science ®Google Scholar
• Ullmann AJ, Lipton JH, Vesole DH, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med. 2007;356:335–347.
   PubMed Web of Science ®Google Scholar
• Maertens JA, Raad II, Marr KA, et al. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. Lancet. 2016;387:760–769.
   PubMed Web of Science ®Google Scholar